A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J, Shi J, Dong D, Fang M, Zhong W, Wang K, Wu N, Huang Y, Liu Z, Cheng Y, Gan Y, Zhou Y, Zhou P, Chen B, Liang C, Liu Z, Li W, Tian J.
Song J, et al.
Clin Cancer Res. 2018 Aug 1;24(15):3583-3592. doi: 10.1158/1078-0432.CCR-17-2507. Epub 2018 Mar 21.
Clin Cancer Res. 2018.
PMID: 29563137